Validity of the UK early access to medicines scheme criteria for Remdesivir use in patients with COVID-19 disease
| Errataetall: |
CommentOn: Clin Infect Dis. 2020 Aug 07;:null. - PMID 32766823 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:81 |
|---|---|
| Enthalten in: |
The Journal of infection - 81(2020), 4 vom: 08. Okt., Seite 647-679 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Daunt, Anna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3QKI37EEHE |
|---|
| Anmerkungen: |
Date Completed 29.09.2020 Date Revised 29.03.2024 published: Print-Electronic CommentOn: Clin Infect Dis. 2020 Aug 07;:null. - PMID 32766823 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jinf.2020.06.049 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311583709 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311583709 | ||
| 003 | DE-627 | ||
| 005 | 20240329233033.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jinf.2020.06.049 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1354.xml |
| 035 | |a (DE-627)NLM311583709 | ||
| 035 | |a (NLM)32579980 | ||
| 035 | |a (PII)S0163-4453(20)30430-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Daunt, Anna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Validity of the UK early access to medicines scheme criteria for Remdesivir use in patients with COVID-19 disease |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.09.2020 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Clin Infect Dis. 2020 Aug 07;:null. - PMID 32766823 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a Clinical deterioration | |
| 650 | 4 | |a Covid-19 | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Remdesivir | |
| 650 | 4 | |a Risk score | |
| 650 | 7 | |a remdesivir |2 NLM | |
| 650 | 7 | |a 3QKI37EEHE |2 NLM | |
| 650 | 7 | |a Adenosine Monophosphate |2 NLM | |
| 650 | 7 | |a 415SHH325A |2 NLM | |
| 650 | 7 | |a Alanine |2 NLM | |
| 650 | 7 | |a OF5P57N2ZX |2 NLM | |
| 700 | 1 | |a Perez-Guzman, Pablo N |e verfasserin |4 aut | |
| 700 | 1 | |a Liew, Felicity |e verfasserin |4 aut | |
| 700 | 1 | |a Hauck, Katharina |e verfasserin |4 aut | |
| 700 | 1 | |a Costelloe, Ceire E |e verfasserin |4 aut | |
| 700 | 1 | |a Thursz, Mark R |e verfasserin |4 aut | |
| 700 | 1 | |a Cooke, Graham |e verfasserin |4 aut | |
| 700 | 1 | |a Nayagam, Shevanthi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infection |d 1982 |g 81(2020), 4 vom: 08. Okt., Seite 647-679 |w (DE-627)NLM012791822 |x 1532-2742 |7 nnns |
| 773 | 1 | 8 | |g volume:81 |g year:2020 |g number:4 |g day:08 |g month:10 |g pages:647-679 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jinf.2020.06.049 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 81 |j 2020 |e 4 |b 08 |c 10 |h 647-679 | ||